<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00544505</url>
  </required_header>
  <id_info>
    <org_study_id>RAC#931-006</org_study_id>
    <nct_id>NCT00544505</nct_id>
  </id_info>
  <brief_title>Pre-operative Chemotherapy in Operable Breast Cancer, Phase III Study Comparing a Short Intensive Pre-operative Chemotherapy With the Same Therapy Initiated Shortly After Surgery(Peri-operatively)(POCOB)EORTC 10902)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Faisal Specialist Hospital &amp; Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King Faisal Specialist Hospital &amp; Research Center</source>
  <brief_summary>
    <textblock>
      Pre-operative chemotherapy in operable breast cancer, phase III study comparing a short&#xD;
      intensive pre-operative chemotherapy with the same therapy initiated shortly after surgery&#xD;
      (peri-operatively) (POCOB) (EORTC 10902)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2007</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy</measure>
    <time_frame>overall</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil/Epirubicin/Cyclophosphamide</intervention_name>
    <description>Phase III Comparison of Preoperative vs Postoperative FEC (Fluorouracil/Epirubicin/Cyclophosphamide) in Women with Operable Breast Cancer</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Disease Characteristics:&#xD;
&#xD;
          -  Palpable, operable breast cancer that has been diagnosed by core needle biopsy&#xD;
             (mandatory for T1c tumors) or fine needle aspiration within 21 days prior to entry&#xD;
&#xD;
          -  Stage T1c-4b, N0-1, M0&#xD;
&#xD;
        Hormone receptor status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
          -  No bilateral breast cancer&#xD;
&#xD;
        Prior/Concurrent Therapy:&#xD;
&#xD;
          -  No previous treatment for breast cancer&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No previous chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Core needle biopsy or fine needle aspiration within 21 days prior to entry&#xD;
&#xD;
          -  Repeated core needle biopsy permitted&#xD;
&#xD;
        Patient Characteristics:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  16 to 70&#xD;
&#xD;
        Sex:&#xD;
&#xD;
          -  Women only&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  WHO 0-2&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 4,000&#xD;
&#xD;
          -  Platelets at least 100,000&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2.8 mg/dL (50 micromoles/L)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.3 mg/dL (120 micromoles/L)&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No significant arrhythmia&#xD;
&#xD;
          -  No bilateral bundle branch block&#xD;
&#xD;
          -  No recent myocardial infarction&#xD;
&#xD;
          -  No uncontrolled hypertension (diastolic pressure greater than 110 mm Hg)&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No male breast cancer&#xD;
&#xD;
          -  No pregnant or nursing women&#xD;
&#xD;
          -  No second malignancy except adequately treated:&#xD;
&#xD;
               -  Nonmelanomatous skin cancer&#xD;
&#xD;
               -  Cervical cancer&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adnan Ezzat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King Faisal Specialist Hospital &amp; Research Center, Riyadh, Saudi Arabia</affiliation>
  </overall_official>
  <verification_date>December 2011</verification_date>
  <study_first_submitted>October 15, 2007</study_first_submitted>
  <study_first_submitted_qc>October 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2007</study_first_posted>
  <last_update_submitted>December 11, 2011</last_update_submitted>
  <last_update_submitted_qc>December 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

